

## ASX / APPENDIX 4C

29 October 2018

The Manager  
Company Announcements Office  
ASX Limited, 20 Bridge St  
SYDNEY NSW 2000

Dear Sir

### APPENDIX 4C

Invion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 30 September 2018.

The Company held cash reserves of \$1.647 million at the end of September, with net operating cash outflows during the quarter of \$1.245 million, consistent with forecasts.

During the quarter the Company announced that initial characterisation of photodynamic therapy, Photosoft™ in ovarian cancer had been completed under its Research & Development Alliance Agreement with the Hudson Institute, with findings showing that Photosoft™ caused efficient and highly effective cancer cell destruction in vitro, with 100% cell death achieved in a matter of minutes following light activation.

Also during the quarter, the Company announced the grant in Australia of the patent for chlorin e4 sodium (Photosoft™ technology), and the completion of the technical transfer of the Photosoft™ technology to a recognised Australian GLP production facility.

### Demerger of Respiratory Assets

In September, the Company announced its plan to demerge its respiratory assets (nadolol and Zafirlukast) into stand-alone company, Chronic Airway Therapeutics Limited (CAT). CAT has been established to focus on development of respiratory assets in China, expediting advancement into Phase 3 clinical trials. Eligible Invion shareholders will, on completion of the demerger, receive one share in Chronic Airway Therapeutics Limited for each Invion share they hold. Shareholders will be voting on resolutions relating to the demerger at the Company's AGM to be held on Tuesday 13 November, in Melbourne.

### Funding

In accordance with strategy, activity in coming quarters will primarily be directed to the clinical development of Photosoft™, the fully burdened costs of which will be funded non-dilutively on a quarterly basis via Invion's R&D services agreement with The Cho Group, a Hong Kong based group that funds and has successfully commercialised a number of unique and advanced technologies.

An Appendix 4C accompanies this announcement.

For and on behalf of the Board of Invion Limited

MELANIE FARRIS  
Company Secretary

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/3/00. Amended 30/9/01, 24/10/05, 17/12/10, 1/09/16

**Name of entity**

INVION LTD

**ABN**

76 094 730 417

**Quarter ended ("current quarter")**

30-September-2018

**Consolidated statement of cash flows**

**1. Cash flows from operating activities**

- 1.1 Receipts from customers
- 1.2 Payments for
  - (a) research and development
  - (b) product manufacturing and operating costs
  - (c) advertising and marketing
  - (d) leased assets
  - (e) staff costs
  - (f) administration and corporate costs
- 1.3 Dividends received (see note 3)
- 1.4 Interest received
- 1.5 Interest and other costs of finance paid
- 1.6 Income taxes paid
- 1.7 Government grants and tax incentives
- 1.8 Other (provide details if material)

**1.9 Net cash from/(used in ) operating activities**

Current quarter	Year to date (12 months)
\$A'000	\$A'000
-	-
(419)	(419)
-	-
-	-
-	-
(171)	(171)
(656)	(656)
-	-
1	1
-	-
-	-
-	-
(1,245)	(1,245)

**2. Cash flows from investing activities**

- 2.1 Payments to acquire:
  - (a) property, plant and equipment
  - (b) businesses (see item 10)
  - (c) investments

-	-
-	-
-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter</b>	<b>Year to date (12 months)</b>
		<b>\$A'000</b>	<b>\$A'000</b>
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		-
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	<b>Net cash from/(used in ) investing activities</b>	-	-
<b>3. Cash flows from financing activities</b>			
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	<b>Net cash from/(used in ) financing activities</b>	-	-
<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>			
4.1	Cash and cash equivalents at beginning of quarter/year to date	2,891	2,891
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,245)	(1,245)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter</b>	<b>Year to date (12 months)</b>
		<b>\$A'000</b>	<b>\$A'000</b>
4.5	Effect of movement in exchange rates on cash held	1	1
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>1,647</b>	<b>1,647</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank Balances	1,647	2,891
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,647</b>	<b>2,891</b>

6. Payments to directors of the entity and their associates		Current quarter \$A'000
6.1	Aggregate amount of payments to the parties included in item 1.2	(168)
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
Payments to directors includes directors fees and executive directors salaries.		

7. Payments to related entities of the entity and their associates		Current quarter \$A'000
7.1	Aggregate amount of payments to the parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

**8. Financing facilities available**

*Add notes as necessary for an understanding of the position*

- 8.1 Loan facilities  
8.2 Credit standby arrangements  
8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Total drawn at quarter end \$A'000
-	-
-	-
-	-

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

**9. Estimated cash outflows for next quarter**

- 9.1 Research and development  
9.2 Product manufacturing and operating costs  
9.3 Advertising and marketing  
9.4 Leased assets  
9.5 Staff costs  
9.6 Administration and corporate costs  
9.7 Other (provide details if material)  
9.8 **Total estimated cash outflows**

\$A'000
660
-
-
-
354
175
-
1,189

**10. Acquisitions and disposals of business entities  
(items 2.1(b) and 2.2(b) above)**

- 10.1 Name of entity  
10.2 Place of incorporation or registration  
10.3 Consideration for acquisition or disposal  
10.4 Total net assets  
10.5 Nature of business

Acquisitions	Disposals
N/A	N/A

## Compliance statement

<sup>1</sup> This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

<sup>2</sup> This statement gives a true and fair view of the matters disclosed.

Sign here: Original signed  
(Company Secretary)



Date: 29-October-2018

Print name: Melanie Farris

## Notes

- <sup>1</sup> The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- <sup>2</sup> If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- <sup>3</sup> Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.